AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00770835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
Study NCT00770835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide and Metformin
Description: Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
Study NCT02121496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources for Postpartum Parenting
Description: The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
Study NCT02079012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-week walking program
Study NCT04293289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CICS-1 (investigational device),SPM-011(investigational drug)
Description: Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
Study NCT01559194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet plus exercise
Description: Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
Study NCT01559194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate diet + Exercise
Description: Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
Study NCT02383589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil Placebo
Description: MMF matching placebo will be administered orally Q12H.
Study NCT02383589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
Study NCT02383589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 1000 mg via IV infusion.
Study NCT02383589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Placebo
Description: Rituximab matching placebo will be administered via IV infusion.
Study NCT02795416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Cosentyx TM
Description: Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month
Study NCT00007813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00007813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00007813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00007813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00007813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT00007813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT04411927 — intervention group
Intervention type: OTHER
Intervention: assessment of postural stability
Description: assessment of postural stability
Study NCT00591825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine
Study NCT00591825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine
Study NCT00591825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04118517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults
Description: The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing >50% of the protein.
Study NCT02592018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
Study NCT04376060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gen-Os®; The soft lamina (OsteoBiol®)
Description: The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects.
Study NCT01802489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Study NCT01802489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical in appearance to Amiloride 10mg capsule
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Description: Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Description: Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Description: Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on a 0- and 28-day schedule
Description: Two doses of placebo at the vaccination schedule of day 0,28
Study NCT04412538 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on a 0- and 14-day schedule
Description: Two doses of placebo at the vaccination schedule of day 0,14
Study NCT02196623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise
Description: Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
Study NCT02196623 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxic Exercise
Description: Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
Study NCT03882710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol XR
Description: Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
Study NCT03882710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol XR
Description: Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
Study NCT00668031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
Study NCT00668031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
Study NCT01557179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalofemme
Description: The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
Study NCT01557179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Estriol cream (Ovestin)
Description: The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
Study NCT02072928 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
Study NCT02427880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide and Hydrochlorothiazide Followed by Furosemide
Study NCT02427880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide and Hydrochlorothiazide Followed by Furosemide
Study NCT01768650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management #1
Description: Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
Study NCT01768650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management #2
Description: Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
Study NCT00450216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/famotidine
Description: HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
Study NCT00450216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 800mg administered orally 3 times daily for 24 weeks
Study NCT03518554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3068
Description: JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
Study NCT00184236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multitreatment approach
Description: 12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
Study NCT00184236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training
Description: Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
Study NCT02909985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tungsten halogen light with narrow bandpass filters
Description: As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
Study NCT01434251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti-hypotensive treatment
Description: Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
Study NCT01434251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypotensive treatment
Description: Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
Study NCT01500850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nph insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Study NCT01500850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal
Study NCT01500850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal
Study NCT01500850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Study NCT01500850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal
Study NCT01500850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal
Study NCT03024476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intensification
Description: Suggested algorithm for behavioral intensification:~* If frequency of BP measurement ≤5 in a week, send a texting message~* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~* Target range of home-systolic blood pressure: 110 - 135~* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management
Study NCT03024476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological intensification based on olmesartan
Description: * Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure >150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule.
Study NCT03024476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bluetooth-equipped sphygmomanometer
Description: * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)
Study NCT03024476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth-equipped sphygmomanometer
Description: * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)
Study NCT03746951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hcl 0.5% Inj Vil 20Ml
Description: Anesthetic agent used in peripheral nerve block
Study NCT02901873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Impedance Spectroscopy
Study NCT04260451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation
Description: Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation.
Study NCT06267287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological examination of the patient's biological material and determination of antibiotic resistance
Description: Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
Study NCT00893438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitNet treatment
Description: web-based cognitive behavioural treatment for adolescents with CFS
Study NCT00893438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care treatment for adolescents with CFS
Study NCT00082225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45 antibodies
Description: The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
Study NCT00082225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV specific T cells
Description: The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2